Pfizer's new at-home pill to treat Covid could be available by end of the year, CEO hopes
The company in March began an early stage clinical trial testing a new antiviral therapy for Covid.
新藥Paxlovid(= nirmatrelvir+ ritonavir)降低住院9成，降低死亡100%。是protease inhibitor。原理與目前C型肝炎口服抗病毒藥物(DAA)很像。HCV RNA 病毒，非結構性蛋白質 NS2、NS3、NS4A、NS4B、NS5A 與 NS5B 會與病毒 RNA 形成複合體，開始病毒複製，所以抗病毒藥物就是作用在這幾個蛋白酶的抑制劑。 新冠肺炎病毒S protein變種太多了，一直針對S portein發展疫苗或是藥物，永遠追不上病毒的速度。如果目前的protease inhibitor可以抑制病毒複製的蛋白酶，就會變成世界救星。
Past 31 days
Total Visit: 0
4000 mark this message contains true information
｜originally written by Lopez
根據CNBC 4/24報導 輝瑞執行長公開宣布：refer [1]
(1)新口服藥進入第一期試驗，如果臨床實驗通過，最快也要年底才能上市。
(2)新口服藥在病發時服用，可以減輕發展成重病的機率，並不能治癒新冠肺炎。
(1)新口服藥進入第一期試驗，如果臨床實驗通過，最快也要年底才能上市。
(2)新口服藥在病發時服用，可以減輕發展成重病的機率，並不能治癒新冠肺炎。
References
[1] https://www.cnbc.com/2021/04/27/pfizer-at-home-covid-pill-could-be-available-by-year-end-ceo-albert-bourla-says.htmlhttps://www.cnbc.com/2021/04/27/pfizer-at-home-covid-pill-could-be-available-by-year-end-ceo-albert-bourla-says.html
The content above by Cofacts message reporting chatbot and crowd-sourced fact-checking community is licensed under Creative Commons Attribution-ShareAlike 4.0 (CC BY-SA 4.0), the community name and the provenance link for each item shall be fully cited for further reproduction or redistribution.
查謠言詐騙